ArticleThoracic cancer2025

Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer.

Zihua Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.